Financial acceleration | BioSeito heard through the Hong Kong Stock Exchange that China Pharmaceutical Valley pressed the “acceleration key” for high-quality industrial development

Aug 10, 2022 18:14

Good news! The invested company BioSeito passed the Hong Kong Stock Exchange listing hearing and strives to become the birthplace of new drugs in the world

Aug 10, 2022 10:14

Biocytogen Pharmaceuticals Refiles for Hong Kong IPO

Dow JonesAug 8, 2022 16:05

Bai Oseatu, heard by HKEx, is about to list Hong Kong IPO.

Bai Osei's income mainly comes from the provision of gene editing services, preclinical pharmacological and efficacy evaluation, model animal sales and antibody development.

瑞恩資本RyanbenCapitalAug 8, 2022 14:16

Express News | Bai Oseatu began to find out investors' demand for its Hong Kong IPO.

BreakingsAug 8, 2022 09:54

With gene editing and "thousands of mice" in hand, the future "birthplace of new drugs in the world" will be heard through the Hong Kong Stock Exchange.

According to the official website of the Hong Kong Stock Exchange (HKEx), Goldman Sachs Group and CICC were co-sponsors of the Bai Oseatu listing hearing through the HKEx on August 7. According to the prospectus, Biosaitu is a biotechnology company that provides preclinical research services and clinical stages. based on high-throughput in vivo antibody discovery platform, proprietary gene editing technology, antibody gene all-human mouse platform and innovative animal model development platform, by providing independent research and development services of animal models and preclinical research and development services to domestic and foreign pharmaceutical companies, and continue to export potential innovative target antibody drug molecules. Committed to becoming the birthplace of new drugs in the world to meet the huge size of the world.

格隆滙Aug 7, 2022 22:47